Corient Private Wealth’s Immunic IMUX Stock Holding History

Corient Private Wealth’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,210	Closed	-$24.5K	–	3145
2026 Q1	$24.5K	Buy	+2,210	New	+$19.8K	﹤0.01%	2778

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Corient Private Wealth's IMUX Position: Q2 2026 in Review

Corient Private Wealth sold out of Immunic (IMUX) in Q2 2026, closing a stake of 2,210 shares — an estimated $24.5K sold.

Corient Private Wealth first reported a position in IMUX in Q1 2026 and held it in 1 quarter. The position peaked at $24.5K in Q1 2026. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

Corient Private Wealth reported no remaining Immunic position as of Q2 2026 after selling out during the quarter.
Corient Private Wealth sold 2,210 Immunic shares in Q2 2026, an estimated $24.5K.
Corient Private Wealth first reported a position in Immunic in Q1 2026 and held it in 1 quarter.
Corient Private Wealth's Immunic position peaked at $24.5K in Q1 2026.
55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.